ArticleJTO clinical and research reports2024

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.

Joel W Neal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.